Patents by Inventor Lawrence M. Kauvar

Lawrence M. Kauvar has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12109265
    Abstract: Treatment of subjects experiencing cerebral ischemia is improved when the treatment employs a thrombolytic and an inhibitor against vascular endothelial growth factor receptor signal transduction (VEGF-RST) at a reduced, low dosage compared to that used to treat cancer patients. The treatment is also improved to permit point-of-care use by formulating protein drugs for long term stability at room temperature, providing doses appropriate for the method, and by combining the therapeutic agents with a point-of-care diagnostic for blood brain barrier integrity.
    Type: Grant
    Filed: August 2, 2021
    Date of Patent: October 8, 2024
    Assignee: Shimojani, LLC
    Inventors: Lawrence M. Kauvar, Damir Janigro
  • Publication number: 20240226877
    Abstract: The present disclosure relates to enhancements in diagnostic assays for detection of analytes. The improved assays are suitable for management of infections and pandemics in humans and animal reservoirs, including but not limited to SARS-CoV-2 (CoV2), and for measurement of biomarkers of disease (both human and veterinary).
    Type: Application
    Filed: October 25, 2023
    Publication date: July 11, 2024
    Applicant: Trellis Bioscience, Inc.
    Inventors: Urs A. Ramel, Joel Blatt, Lawrence M. Kauvar, Stote Ellsworth, Ralph A. Tripp, Leslie P. Jones
  • Publication number: 20240150414
    Abstract: X-ray crystallography has defined conformational properties of a key functional region of the G protein of respiratory syncytial virus (RSV). Mimics of these epitopes have utility as immunogens, as tools for discovery of antibodies and other monoclonal binding agents, and as pharmacological agents to modulate activity of the host receptors for this viral protein.
    Type: Application
    Filed: August 19, 2023
    Publication date: May 9, 2024
    Applicants: Trellis Bioscience, Inc., The Regents of the University of California
    Inventors: Rebecca DUBOIS, Stas FEDECHKIN, Lawrence M. KAUVAR
  • Publication number: 20240131508
    Abstract: The present disclosure relates to enhancements in diagnostic assays for detection of analytes. The improved assays are suitable for management of infections and pandemics in humans and animal reservoirs, including but not limited to SARS-CoV-2 (CoV2), and for measurement of biomarkers of disease (both human and veterinary).
    Type: Application
    Filed: October 24, 2023
    Publication date: April 25, 2024
    Applicant: Trellis Bioscience, Inc.
    Inventors: Urs A. Ramel, Joel Blatt, Lawrence M. Kauvar, Stote Ellsworth, Ralph A. Tripp, Leslie P. Jones
  • Patent number: 11773143
    Abstract: X-ray crystallography has defined conformational properties of a key functional region of the G protein of respiratory syncytial virus (RSV). Mimics of these epitopes have utility as immunogens, as tools for discovery of antibodies and other monoclonal binding agents, and as pharmacological agents to modulate activity of the host receptors for this viral protein.
    Type: Grant
    Filed: October 12, 2018
    Date of Patent: October 3, 2023
    Assignees: Trellis Bioscience, LLC, The Regents of the University of California
    Inventors: Rebecca Dubois, Stas Fedechkin, Lawrence M. Kauvar
  • Patent number: 11725055
    Abstract: Monoclonal antibodies derived from the native human repertoire that bind the extracellular portion of Killer IgG Receptor (KIR) and pharmaceutical and veterinary compositions thereof are useful in treating cancer in human and other subjects.
    Type: Grant
    Filed: November 6, 2020
    Date of Patent: August 15, 2023
    Inventors: Angeles Estelles, Mikhail Gishizky, Stefan Ryser, Lawrence M. Kauvar
  • Publication number: 20220259294
    Abstract: Binding agents able to disrupt bacterial biofilms of diverse origin are described, including monoclonal antibodies secreted by human B lymphocytes. Methods to prevent formation of or to dissolve biofilms with these binding agents are also described. Immunogens for eliciting antibodies to disrupt biofilms are also described.
    Type: Application
    Filed: January 5, 2022
    Publication date: August 18, 2022
    Applicant: TRELLIS BIOSCIENCE, LLC
    Inventors: Lawrence M. KAUVAR, Stefan RYSER, Angeles ESTELLES, Reyna J. SIMON, Lauren Opremcak BAKALETZ, Steven David GOODMAN
  • Publication number: 20220204600
    Abstract: The present disclosure is directed to an aqueous therapeutic protein formulation including: (i) one or more therapeutic proteins, wherein the one or more therapeutic proteins include one or more anti-DNABII antibodies or antigen-binding fragments thereof in an amount ranging from 10 to 150 mg/mL; (ii) histidine buffer, (iii) NaCl, and (iv) an aqueous carrier, wherein a pH of the aqueous therapeutic formulation ranges from 5.5-8.0, and wherein the formulation is formulated for respiratory tract delivery and produces particles including the one or more therapeutic proteins upon aerosolization. Methods of generating an aerosol and treating biofilm-associated diseases or disorders, e.g., cystic fibrosis, ventilator-associated pneumonia, and acute exarcebations of chronic obstructive pulmonary disease or chronic bronchitis are also provided.
    Type: Application
    Filed: December 29, 2021
    Publication date: June 30, 2022
    Applicant: Trellis Bioscience, Inc.
    Inventors: Lawrence M. Kauvar, Stefan Ryser
  • Publication number: 20220111049
    Abstract: Antibodies, compositions and methods are provided for treatment and prophylaxis of influenza virus. Antibodies and antigen-binding fragments are provided that bind near the HA0 maturation cleavage site consensus sequence of influenza hemagglutinin A. Antibody compositions, combinations and methods for effective passive immunization across influenza A and B strains are also provided.
    Type: Application
    Filed: December 23, 2021
    Publication date: April 14, 2022
    Inventors: Angeles Estelles, Lawrence M. Kauvar, Adam Vigil, Michael Wittekind
  • Patent number: 11246928
    Abstract: Antibodies, compositions and methods are provided for treatment and prophylaxis of influenza virus. Antibodies and antigen-binding fragments are provided that hind near the HA0 maturation cleavage site consensus sequence of influenza hemagglutinin A. Antibody compositions, combinations and methods for effective passive immunization across influenza A and B strains are also provided.
    Type: Grant
    Filed: November 5, 2019
    Date of Patent: February 15, 2022
    Assignees: CONTRAFECT CORPORATION, TRELLIS BIOSCIENCE, LLC
    Inventors: Angeles Estelles, Lawrence M. Kauvar, Adam Vigil, Michael Wittekind
  • Patent number: 11248040
    Abstract: Binding agents able to disrupt bacterial biofilms of diverse origin are described, including monoclonal antibodies secreted by human B lymphocytes. Methods to prevent formation of or to dissolve biofilms with these binding agents are also described. Immunogens for eliciting antibodies to disrupt biofilms are also described.
    Type: Grant
    Filed: January 17, 2020
    Date of Patent: February 15, 2022
    Assignee: TRELLIS BIOSCIENCE, LLC
    Inventors: Lawrence M. Kauvar, Stefan Ryser, Angeles Estelles, Reyna J. Simon, Lauren Opremcak Bakaletz, Steven David Goodman
  • Publication number: 20210361769
    Abstract: Treatment of subjects experiencing cerebral ischemia is improved when the treatment employs a thrombolytic and an inhibitor against vascular endothelial growth factor receptor signal transduction (VEGF-RST) at a reduced, low dosage compared to that used to treat cancer patients. The treatment is also improved to permit point-of-care use by formulating protein drugs for long term stability at room temperature, providing doses appropriate for the method, and by combining the therapeutic agents with a point-of-care diagnostic for blood brain barrier integrity.
    Type: Application
    Filed: August 2, 2021
    Publication date: November 25, 2021
    Applicant: Shimojani, LLC
    Inventors: Lawrence M. KAUVAR, Damir JANIGRO
  • Publication number: 20210277116
    Abstract: Novel monoclonal antibodies directed against immune checkpoint modulator (ICM) proteins TIM-3 and B7-H3 are useful in treating cancer and immune system disorders.
    Type: Application
    Filed: May 24, 2021
    Publication date: September 9, 2021
    Applicant: TRELLIS BIOSCIENCE, LLC
    Inventors: Angeles ESTELLES, Mikhail GISHIZKY, Stefan RYSER, Lawrence M. KAUVAR
  • Publication number: 20210268096
    Abstract: Improvements to vaccines against RSV include G protein CCD portions complexed with mAb that block interaction with CX3C-R and modified forms of mAb to prolong serum half-life, as well as inhalable vaccines.
    Type: Application
    Filed: February 5, 2021
    Publication date: September 2, 2021
    Applicant: Trellis Bioscience, LLC
    Inventors: Milton J. Friedman, Lawrence M. Kauvar
  • Patent number: 11077188
    Abstract: Treatment of subjects experiencing cerebral ischemia is improved when the treatment employs a thrombolytic and an inhibitor against vascular endothelial growth factor receptor signal transduction (VEGF-RST) at a reduced, low dosage compared to that used to treat cancer patients. The treatment is also improved to permit point-of-care use by formulating protein drugs for long term stability at room temperature, providing doses appropriate for the method, and by combining the therapeutic agents with a point-of-care diagnostic for blood brain barrier integrity.
    Type: Grant
    Filed: April 7, 2020
    Date of Patent: August 3, 2021
    Assignee: Shimojani, LLC
    Inventors: Lawrence M. Kauvar, Damir Janigro
  • Patent number: 11046764
    Abstract: Novel monoclonal antibodies directed against immune checkpoint modulator (ICM) proteins TIM-3 and B7-H3 are useful in treating cancer and immune system disorders.
    Type: Grant
    Filed: January 3, 2018
    Date of Patent: June 29, 2021
    Assignee: Trellis Bioscience, LLC
    Inventors: Angeles Estelles, Mikhail Gishizky, Stefan Ryser, Lawrence M. Kauvar
  • Publication number: 20210054075
    Abstract: Monoclonal antibodies derived from the native human repertoire that bind the extracellular portion of Killer IgG Receptor (KIR) and pharmaceutical and veterinary compositions thereof are useful in treating cancer in human and other subjects.
    Type: Application
    Filed: November 6, 2020
    Publication date: February 25, 2021
    Applicant: Trellis Bioscience, LLC
    Inventors: Angeles ESTELLES, Mikhail GISHIZKY, Stefan RYSER, Lawrence M. KAUVAR
  • Patent number: 10858431
    Abstract: Monoclonal antibodies derived from the native human repertoire that bind the extracellular portion of Killer IgG Receptor (KIR) and pharmaceutical and veterinary compositions thereof are useful in treating cancer in human and other subjects.
    Type: Grant
    Filed: June 9, 2017
    Date of Patent: December 8, 2020
    Assignee: Trellis Bioscience, LLC
    Inventors: Angeles Estelles, Mikhail Gishizky, Stefan Ryser, Lawrence M. Kauvar
  • Publication number: 20200230237
    Abstract: Treatment of subjects experiencing cerebral ischemia is improved when the treatment employs a thrombolytic and an inhibitor against vascular endothelial growth factor receptor signal transduction (VEGF-RST) at a reduced, low dosage compared to that used to treat cancer patients. The treatment is also improved to permit point-of-care use by formulating protein drugs for long term stability at room temperature, providing doses appropriate for the method, and by combining the therapeutic agents with a point-of-care diagnostic for blood brain barrier integrity.
    Type: Application
    Filed: April 7, 2020
    Publication date: July 23, 2020
    Applicant: Shimojani, LLC
    Inventors: Lawrence M. KAUVAR, Damir JANIGRO
  • Publication number: 20200190170
    Abstract: Binding agents able to disrupt bacterial biofilms of diverse origin are described, including monoclonal antibodies secreted by human B lymphocytes. Methods to prevent formation of or to dissolve biofilms with these binding agents are also described. Immunogens for eliciting antibodies to disrupt biofilms are also described.
    Type: Application
    Filed: January 17, 2020
    Publication date: June 18, 2020
    Applicant: TRELLIS BIOSCIENCE, LLC
    Inventors: Lawrence M. KAUVAR, Stefan RYSER, Angeles ESTELLES, Reyna J. SIMON, Lauren Opremcak BAKALETZ, Steven David GOODMAN